<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H6AA70B2DE3D14BA0A044CEDACC2166A2" public-private="public" key="H" bill-type="olc">
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 1805 IH: Leo’s Law</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-03-27</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code>
<congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session>
<legis-num display="yes">H. R. 1805</legis-num>
<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
<action display="yes">
<action-date date="20230327">March 27, 2023</action-date>
<action-desc><sponsor name-id="G000583">Mr. Gottheimer</sponsor> (for himself and <cosponsor name-id="B001298">Mr. Bacon</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
</action>
<legis-type>A BILL</legis-type>
<official-title display="yes">To mitigate the effects of the COVID–19 pandemic on incentives under the Federal Food, Drug, and Cosmetic Act for the development of orphan drugs, and for other purposes.</official-title>
</form>
<legis-body id="H80A360DAA44146578822CAED19AB234E" style="OLC"> 
<section id="H08D22E8AC38D40DB90567547D034258B" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as <quote><short-title>Leo’s Law</short-title></quote>.</text></section> <section id="H594ACA7ED14647FF895276CD81B31ED3"><enum>2.</enum><header>Mitigation of effects of COVID–19 pandemic on orphan-drug development incentives</header> <subsection id="H850BF98911FE46BA9B4689A941D30C4A"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">In the case of a covered orphan drug, each of the following exclusivity periods is deemed to be extended by 180 days, so long as such period is not expired:</text> 
<paragraph id="HDFBC454393064F8BACE2232C3AE37585"><enum>(1)</enum><text display-inline="yes-display-inline">The 12-year period referred to in subparagraph (A) of section 351(k)(7) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)(7)</external-xref>).</text></paragraph> <paragraph id="H060DBBD92EAE48728D53900AAA72D247"><enum>(2)</enum><text display-inline="yes-display-inline">The 5-year period referred to in subsection (c)(3)(E)(ii) and subsection (j)(5)(F)(ii) of section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>).</text></paragraph> 
<paragraph id="H9EEB373F78484076824D5A05272BF1BA"><enum>(3)</enum><text display-inline="yes-display-inline">The 3-year period referred to in each of clauses (iii) and (iv) of subsection (c)(3)(E) and clauses (iii) and (iv) of subsection (j)(5)(F) of section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>).</text></paragraph> <paragraph id="H1D8E527B68DE4142A6FACE67BED70997"><enum>(4)</enum><text display-inline="yes-display-inline">The 7-year period referred to in section 527(a) of the Federal, Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360cc">21 U.S.C. 360cc</external-xref>).</text></paragraph> 
<paragraph id="HC33551FD3386401BB74875E4E2CFAAC7"><enum>(5)</enum><text display-inline="yes-display-inline"><italic></italic>In the case of a covered orphan drug with one or more certifications specified in clauses (ii), (iii), and (iv) of section 505(b)(2)(A) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(b)(2)(A)</external-xref>), or in subclauses (II), (III), and (IV) of section 505(j)(2)(A)(vii) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)(2)(A)(vii)</external-xref>), each corresponding patent-related approval-delay period (other than a patent for which the information required pursuant to subsection (b) or (c) of section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) has not been filed).</text></paragraph></subsection> <subsection id="H1A8DB85EE1FA434D9D85FB4ED50916DC"><enum>(b)</enum><header>Conforming extensions</header><text>In addition to the periods extended under subsection (a) for a covered orphan drug, the following periods are each deemed to be extended by 180 days:</text> 
<paragraph id="H7EBA700678B84EB8A2199D8C15E95A52"><enum>(1)</enum><text display-inline="yes-display-inline">The 4-year period referred to in subparagraph (B) of section 351(k)(7) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)(7)</external-xref>).</text></paragraph> <paragraph id="H7105D0AD461C457DA837120F0A9FC32F"><enum>(2)</enum><text>The 4-year, 48-month, and 7 and one-half-year periods referred to in subsection (c)(3)(E)(ii) and subsection (j)(5)(F)(ii) of section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>).</text></paragraph></subsection> 
<subsection id="H04BE3FFDF9444BB8944713FDF19E03E3" commented="no"><enum>(c)</enum><header>Definitions</header><text>In this section:</text> <paragraph id="H5667005C13684F9FB318B94202D11255" commented="no"><enum>(1)</enum><text>The term <term>covered orphan drug</term> means an orphan drug for which—</text> 
<subparagraph id="H190B65372FE24C4D8D17D7BE7A3FEE30" commented="no"><enum>(A)</enum><text display-inline="yes-display-inline">an application is submitted under section 505(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(i)</external-xref>) during the COVID–19 emergency period (without regard to whether the same applicant has submitted such applications for the same drug before December 1, 2019, for a different rare disease or condition);</text></subparagraph> <subparagraph id="HC7E572856E7F45EA9D7E12282D9AA26F" commented="no"><enum>(B)</enum><text>an application under section 505(b) of the Federal Food, Drug, and Cosmetic Act or under section 351(a) of the Public Health Service Act (or a supplemental application, as the case may be) is approved pursuant to the investigational new drug application referred to in paragraph (1); and</text></subparagraph> 
<subparagraph id="HD30E98B95FFC4D5AACBA7A850181A358" commented="no"><enum>(C)</enum><text>there is no approved indication that is not for a rare disease or condition.</text></subparagraph></paragraph> <paragraph id="H1873A1E6414F4F70883810C27460CB72" commented="no"><enum>(2)</enum><text display-inline="yes-display-inline"><italic></italic>The term <term>corresponding patent-related approval delay period</term>, with respect to a covered orphan drug, means the period ending with the last applicable date for the approval of an application within the meaning of subparagraph (A), (B), or (C) of section 505(c)(3) of the Federal, Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(c)(3)</external-xref>), or clause (i), (ii), or (iii) of section 505(j)(5)(B) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)(5)(B)</external-xref>), whichever applies pursuant to the applicable patent certification.</text></paragraph> 
<paragraph id="HB011D2B8DA224FC787032503DED77F9D" commented="no"><enum>(3)</enum><text display-inline="yes-display-inline">The term <term>orphan drug</term> means a drug that the Secretary has designated as a drug for a rare disease or condition under section 526(a) of the Federal, Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bb">21 U.S.C. 360bb(a)</external-xref>).</text></paragraph> <paragraph id="HD37EBF4700714F798192ADD12C9D7941" commented="no"><enum>(4)</enum><text display-inline="yes-display-inline">The term <term>COVID–19 emergency period</term> means the period beginning on December 1, 2019, and ending on the date that is not later than 120 days before the date on which the emergency period (as defined in section 1135(g)(1)(B) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1320b-5">42 U.S.C. 1320b–5(g)(1)(B)</external-xref>)) terminates.</text></paragraph> 
<paragraph id="H769E689A1B664AA69877E920FF94237D" commented="no"><enum>(5)</enum><text>The term <term>rare disease or condition</term> has the meaning given such term in section 526 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bb">21 U.S.C. 360bb</external-xref>).</text></paragraph></subsection> <subsection id="H5A1CC031B0DC46AE9E0C66952369A5A6"><enum>(d)</enum><header>Effective date</header><text>This section takes effect upon the date of the enactment of this Act, without regard to whether the Secretary has issued guidance or regulations regarding the implementation of this Act.</text></subsection></section> 
</legis-body>
</bill> 


